Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13
Artelo Biosciences has received a Notice of Allowance from the European Patent Office for its patent application covering the commercial formulation of ART27.13, a cannabinoid agonist in Phase 2 trials for cancer-related anorexia. The patent extends protection until December 2041, enhancing the drug's commercial potential. ART27.13 aims to address a significant unmet need, as there are currently no approved therapies for cancer-related anorexia in major markets. Initial results from the ongoing clinical trial are expected in Q3 2025.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments